Last reviewed · How we verify
Sulfurine (SULFAMETHIZOLE)
At a glance
| Generic name | SULFAMETHIZOLE |
|---|---|
| Drug class | sulfamethizole |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Acute otitis media
- Bacterial urinary infection
- Escherichia coli urinary tract infection
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus Influenzae Chronic Bronchitis
- Infective otitis media
- Klebsiella cystitis
- Morganella Morganii Urinary Tract Infection
- Pneumocystis Carinii Pneumonia Prevention
- Pneumocystosis jiroveci pneumonia
- Proteus urinary tract infection
- Shigellosis
- Streptococcus Pneumoniae Chronic Bronchitis
Common side effects
Drug interactions
- methotrexate
- pralatrexate
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfurine CI brief — competitive landscape report
- Sulfurine updates RSS · CI watch RSS